Published in Hypertens Pregnancy on May 01, 2013
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
The imbalance of circulating angiogenic/antiangiogenic factors is mild or absent in obese women destined to develop preeclampsia. Hypertens Pregnancy (2014) 1.05
Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens (2013) 0.79
Placental disease and the maternal syndrome of preeclampsia: missing links? Curr Hypertens Rep (2013) 0.79
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn (2015) 0.78
Urinary Concentrations of Bisphenol A and Phthalate Metabolites Measured during Pregnancy and Risk of Preeclampsia. Environ Health Perspect (2016) 0.78
Intraplacental gene therapy with Ad-IGF-1 corrects naturally occurring rabbit model of intrauterine growth restriction. Hum Gene Ther (2015) 0.77
A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy. J Nephrol (2017) 0.77
Maternal Smoking during Pregnancy and Daughters' Preeclampsia Risk. PLoS One (2015) 0.76
Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clin J Am Soc Nephrol (2016) 0.75
Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". Hypertens Pregnancy (2014) 0.75
Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. Int J Mol Sci (2015) 0.75
Cluster analysis to estimate the risk of preeclampsia in the high-risk Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. PLoS One (2017) 0.75
Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol (2015) 0.75
Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res (2016) 0.75
Prevalence of pregnancy hypertensive disorders in Mongolia. Pregnancy Hypertens (2016) 0.75
Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol (2002) 7.40
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med (2010) 3.81
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Management of obesity in pregnancy. Obstet Gynecol (2007) 2.49
Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) (1981) 2.33
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation (2010) 1.74
The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol (2007) 1.65
Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol (2008) 1.60
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A (2010) 1.56
Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy (2007) 1.25
Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension (2012) 1.14
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13
Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol (2008) 1.05
Lupus nephritis and renal disease in pregnancy. Lupus (2006) 0.99
[Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience]. Z Geburtshilfe Neonatol (2011) 0.97
Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension (2012) 0.96
Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int (2012) 0.95
Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med (2012) 0.95
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One (2012) 0.94
Diabetes and the kidney in pregnancy. Semin Nephrol (2011) 0.89
Renal lesions in the hypertensive syndromes of pregnancy: immunomorphological and ultrastructural studies in 114 cases. Clin Nephrol (1980) 0.88
Early onset pre-eclampsia: recognition of underlying renal disease. Br Med J (Clin Res Ed) (1987) 0.84
Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1/placental growth factor ratio. Hypertension (2012) 0.83
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Transcriptional control of preadipocyte determination by Zfp423. Nature (2010) 3.55
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med (2016) 2.99
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Assessing the impact of protocol design changes on clinical trial performance. Am J Ther (2008) 2.60
Confocal light absorption and scattering spectroscopic microscopy monitors organelles in live cells with no exogenous labels. Proc Natl Acad Sci U S A (2007) 2.56
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A (2009) 2.50
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab (2010) 2.06
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol (2004) 2.03
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Metabolic signatures of exercise in human plasma. Sci Transl Med (2010) 1.99
Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature (2011) 1.98
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation (2009) 1.85
Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int (2010) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab (2002) 1.79
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis (2012) 1.72
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70